BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company specializing in novel antibacterials for serious infections caused by multidrug-resistant (MDR) bacteria, announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference. The conference, scheduled for September 14-16, 2026, in New York City, will feature a presentation by BioVersys' Chief Financial Officer, Hernan Levett, on September 16, 2026, from 12:30 PM to 1:00 PM ET at the Kennedy II room of the Lotte New York Palace. Additionally, Chief Executive Officer Dr. Marc Gitzinger will deliver an on-demand presentation beginning September 11, 2026, accessible via the H.C. Wainwright platform or the BioVersys website in the investor section, with replays available for 90 days.
The presentation underscores BioVersys' commitment to addressing the critical unmet medical need for new treatments against life-threatening resistant bacterial infections. The company's pipeline includes BV100, a Phase 3 candidate targeting nosocomial infections caused by Acinetobacter baumannii, and alpibectir, a Phase 2 candidate for tuberculosis developed in collaboration with GlaxoSmithKline (GSK) and a consortium led by the University of Lille, France. These programs leverage BioVersys' proprietary technology platforms, TRIC and Ansamycin Chemistry, designed to overcome resistance mechanisms, block virulence production, and directly affect bacterial pathogenesis.
The conference provides a platform for BioVersys to highlight its progress and strategic direction to the investment community. With the rise of antimicrobial resistance posing a global health threat, the company's work is particularly salient. According to the World Health Organization, antimicrobial resistance is one of the top 10 global public health threats, and innovative approaches like those being developed by BioVersys are essential to combat this crisis. The company's focus on both hospital-acquired infections and tuberculosis, which remain major causes of morbidity and mortality worldwide, positions it as a key player in the antibacterial space.
BioVersys' participation in the conference also offers an opportunity for investors to engage with management. The CEO and CFO will be available for one-on-one meetings with registered attendees, allowing for deeper discussions on the company's clinical programs, regulatory strategy, and market opportunities. This engagement is crucial as BioVersys advances its late-stage pipeline and seeks to bring novel treatments to patients in need.
The company's Basel, Switzerland headquarters places it in a prominent biotech hub, facilitating collaborations and access to talent. BioVersys' commitment to developing first-in-class treatments is reflected in its robust pipeline and strategic partnerships. As it continues to progress its clinical trials, the outcomes of these efforts could significantly impact the management of drug-resistant infections, potentially saving countless lives.
The H.C. Wainwright conference is a notable event in the financial calendar, bringing together investors and innovative companies from the healthcare sector. For BioVersys, this is a chance to showcase its value proposition and to highlight the importance of continued investment in antimicrobial research. With the threat of antibiotic resistance growing, the need for new therapies has never been greater, and BioVersys is at the forefront of addressing this challenge.
